Mesenchymal stem cells for acute lung injury: preclinical evidence

Crit Care Med. 2010 Oct;38(10 Suppl):S569-73. doi: 10.1097/CCM.0b013e3181f1ff1d.


Several experimental studies have suggested that mesenchymal stem cells may have value for the treatment of clinical disorders, including myocardial infarction, diabetes, acute renal failure, sepsis, and acute lung injury. In preclinical studies, mesenchymal stem cells have been effective in reducing lung injury from endotoxin, live bacteria, bleomycin, and hyperoxia. In some studies, the cultured medium from mesenchymal stem cells has been as effective as the mesenchymal stem cells themselves. Several paracrine mediators that can mediate the effect of mesenchymal stem cells have been identified, including interleukin-10, interleukin-1ra, keratinocyte growth factor, and prostaglandin E2. Further preclinical studies are needed, as is planning for clinical trials for acute lung injury.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Acute Kidney Injury / therapy
  • Acute Lung Injury / therapy*
  • Animals
  • Disease Models, Animal
  • Endotoxins / pharmacology
  • Humans
  • Lung / drug effects
  • Mesenchymal Stem Cell Transplantation*
  • Mesenchymal Stem Cells / physiology
  • Mice
  • Sepsis / therapy


  • Endotoxins